BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29574693)

  • 1. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.
    Rowland A; van Dyk M; Hopkins AM; Mounzer R; Polasek TM; Rostami-Hodjegan A; Sorich MJ
    Clin Pharmacol Ther; 2018 Dec; 104(6):1219-1228. PubMed ID: 29574693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
    Ouellet D; Gibiansky E; Leonowens C; O'Hagan A; Haney P; Switzky J; Goodman VL
    J Clin Pharmacol; 2014 Jun; 54(6):696-706. PubMed ID: 24408395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
    Nebot N; Arkenau HT; Infante JR; Chandler JC; Weickhardt A; Lickliter JD; Sarantopoulos J; Gordon MS; Mak G; St-Pierre A; Tang L; Mookerjee B; Carson SW; Hayes S; Grossmann KF
    Br J Clin Pharmacol; 2018 Apr; 84(4):764-775. PubMed ID: 29243287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
    Suttle AB; Grossmann KF; Ouellet D; Richards-Peterson LE; Aktan G; Gordon MS; LoRusso PM; Infante JR; Sharma S; Kendra K; Patel M; Pant S; Arkenau HT; Middleton MR; Blackman SC; Botbyl J; Carson SW
    J Clin Pharmacol; 2015 Apr; 55(4):392-400. PubMed ID: 25449654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
    Sorf A; Vagiannis D; Ahmed F; Hofman J; Ceckova M
    Toxicol Appl Pharmacol; 2022 Jan; 434():115797. PubMed ID: 34780725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
    Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
    Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
    Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
    J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
    Denton CL; Minthorn E; Carson SW; Young GC; Richards-Peterson LE; Botbyl J; Han C; Morrison RA; Blackman SC; Ouellet D
    J Clin Pharmacol; 2013 Sep; 53(9):955-61. PubMed ID: 23846776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.
    Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):926-940. PubMed ID: 38482980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
    White-Koning M; Civade E; Geoerger B; Thomas F; Le Deley MC; Hennebelle I; Delord JP; Chatelut E; Vassal G
    Clin Cancer Res; 2011 Jul; 17(14):4862-71. PubMed ID: 21653689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
    Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
    Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
    Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
    J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
    Lu C; Suri A; Shyu WC; Prakash S
    Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
    Puszkiel A; Noé G; Bellesoeur A; Kramkimel N; Paludetto MN; Thomas-Schoemann A; Vidal M; Goldwasser F; Chatelut E; Blanchet B
    Clin Pharmacokinet; 2019 Apr; 58(4):451-467. PubMed ID: 30094711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
    Ouellet D; Grossmann KF; Limentani G; Nebot N; Lan K; Knowles L; Gordon MS; Sharma S; Infante JR; Lorusso PM; Pande G; Krachey EC; Blackman SC; Carson SW
    J Pharm Sci; 2013 Sep; 102(9):3100-9. PubMed ID: 23608920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.
    Sorich MJ; Mutlib F; van Dyk M; Hopkins AM; Polasek TM; Marshall JC; Rodrigues AD; Rowland A
    J Clin Pharmacol; 2019 Jun; 59(6):872-879. PubMed ID: 30633368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.
    Lilly E; Burke M; Kluger H; Choi J
    JAMA Dermatol; 2015 Jan; 151(1):102-3. PubMed ID: 25250477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.